Overview / Abstract: |
How can clinicians know they have current information for improving patients’ IBD outcomes? Expert faculty from the Icahn School of Medicine at Mount Sinai, University of Chicago Medicine and Biological Sciences, and Montefiore Medical Center/Albert Einstein College of Medicine recently led a symposium at a major gastroenterology meeting exploring the latest in treat-to-target paradigms, the role of the JAK-STAT pathway, and related research on investigational JAK inhibitors in IBD treatment. Video excerpts from the symposium are available as modules making it easier for the learner to move easily from one excerpt to another. |
Expiration |
Jun 27, 2020 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Webinar / Webcast / Video |
Credits / Hours |
1.0 |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Bruce Sands, MD, MS Joel Pekow, MD Thomas Ullman, MD |
Sponsors / Supporters / Grant Providers |
Supported by an educational grant from Gilead Sciences, Inc. |
Keywords / Search Terms |
ACHL inflammatory disease, inflammatory bowel disease, IBD, crohn’s disease, ulcerative colitis, signaling pathway, JAK inhibitor, inflammatory diseases, autoimmune disorders, janus kinase, therapies, immune-mediated inflammatory diseases, JAK1, JAK2, JAK3, TYK2, JAK/STAT signaling, cytokine-mediated inflammatory diseases, DMARDs, chronic inflammation, emerging therapies, gastroenterology, digestive disorders, inflammatory bowel Free CE CME |